Artwork Document Information	Artwork Type [Please Tick /]	Sign / Stamp
Product : T ORAL AID LOTION SAP No. : Date : 06 October 2025	☐ Unit Box ☑ Leaflet ☐ Aluminium Foil ☐ Generic Box ☐ Outer Box ☐ Fix-A-Form ☐ Sachet ☐ Label ☐ Shipper Carton ☐ Others : _____	

Document Category [Please Tick /]	Pharmacode / QR Code / Others Info
☑ RA/NPRA Artwork ☐ Recirculation Artwork ☐ Approval Copy Artwork ☐ Clean Copy ☐ Internal Artwork Circulation ☐ Previous Approved Artwork ☐ Draft Artwork ☐ Others : _____	

Remarks	Colour
1. Font : Adobe Garamond Pro (Spacing - 6.5pt / Size - 5.5pt) 2. Dimension : 163mm(w) x 127mm(h)	Black Colours shown on this proof are to indicate correct colour separations.

ORAL AID LOTION

DESCRIPTION

A milky white, flavoured, homogeneous, colloidal solution. It contains Lignocaine 2.5% w/v, Chlorhexidine HCl 0.5% w/v and Triamcinolone Acetonide 0.1% w/v.

INDICATIONS

Oral Aid Lotion is an anaesthetic, antibacterial, and anti-inflammatory agent, which is used in mouth infections or oral lesions. It heals and relieves pain and discomfort in acute and chronic lesions of the gum, palate, cheek and tongue.

PHARMACODYNAMICS

Lignocaine HCl
Local anaesthethics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilises the membrane and inhibits depolarisation, resulting in conduction blockade.
Chlorhexidine HCl
Because of its positive charge, chlorhexidine is adsorbed onto the surfaces of teeth, plaque, and oral mucosa, which is gradually released from these sites for up to 24 hours, providing a continuing bacteriostatic effect.
Triamcinolone Acetonide
Corticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors, resulting in antiinflammatory effects of Oral Aid Lotion.

DOSAGE

Adult: Apply to the affected area, up to every one to two hours as required.
Route of administration: For External Use

SIDE EFFECTS

Side effects of Oral Aid Lotion include allergic contact dermatitis (skin rash, redness, itching, or hives), angioedema (large, hive-like swellings on skin or in mouth or throat), burning, stinging, swelling, or tenderness not present before therapy. Transient taste disturbances and a burning sensation of the tongue may occur on initial use.
Immune System Disorders
- Frequency not known: Hypersensitivity including anaphylactic shock.

CONTRAINDICATIONS

Oral Aid Lotion is contraindicated in patients who are sensitive to lignocaine, chlorhexidine and triamcinolone acetonide.

WARNINGS AND PRECAUTIONS

Oral Aid Lotion should be used with caution when there is local infection at area of treatment. Caution is also needed when there is severe traumatized mucosa as it may increase absorption of anaesthetic, leading to increased risk of systematic toxicity. Herpes simplex at treatment site may be transmitted to other sites, including the eye. Again, caution is needed in patients with anterior tooth restorations (front-tooth fillings) and periodontitis.

Oral Aid Lotion contains chlorhexidine. Chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock. The prevalence of chlorhexidine hypersensitivity is unknown, but available literature suggests this is likely to be very rare. Oral Aid Lotion should not be administered to anyone with a possible history of an allergic reaction to chlorhexidine.
If any signs or symptoms of a suspected hypersensitivity reaction such as itching, skin rash, redness, swelling, breathing difficulties, light headedness, and rapid heart rate develop, immediately stop using the product. Appropriate therapeutic counter measures must be instituted as clinically indicated.

DRUG INTERACTIONS

At recommended doses, drug interactions are uncommon. However, in rare cases where Oral Aid Lotion is used in large quantities, used repeatedly or swallowed, lignocaine is systemically absorbed and interactions with beta-adrenergic blocking agents, cimetidine, and other amide local anaesthetic-derivative antiarrythmic agents have been reported. Long term administration of enzyme-inducing agents such as phenytoin may increase dosage requirements of lignocaine.
Co-treatment with CYP3A inhibitors, including cobicistat-containing product, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefits outweighs the increased risk of systemic corticosteroid side effects, in which case patients should be monitored for systemic corticosteroid side-effects.

OVERDOSAGE

When used as recommended, overdosing with Oral Aid Lotion is rare.

PRESENTATION

5ml x 12 units and 6ml x 12 units (Not all pack sizes available locally).

STORAGE CONDITIONS AND USER INSTRUCTIONS

Keep container tightly closed.
Store in a dry place below 30°C.
Protect from light.
Keep out of reach of children.
Jauhi daripada kanak-kanak.
Shelf life : Please refer to outer package.

Product Registration Holder:
Duopharma Manufacturing (Bangi) Sdn.Bhd.
Lot No. 2, 4, 6, 8 & 10, Jalan P/7, Section 13, Bangi Industrial Estate,
43650 Bandar Baru Bangi, Selangor, Malaysia.

Manufacturer:
Duopharma Manufacturing (Bangi) Sdn.Bhd.
Lot No. 2 & 4, Jalan P/7, Section 13, Bangi Industrial Estate,
43650 Bandar Baru Bangi, Selangor, Malaysia.

Revision Date: October 2025

DUOPHARMA